Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 11 - 09 tags : Trial save search
Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Published: 2021-11-09 (Crawled : 00:20) - ir.vaccinex.com
VCNX | $4.9631 2.8K
|
Health Technology
|
| O: -0.51%
H: 5.08%
C: 4.06%
disease alzheimer clinical trials vaccine trials trial alzheimer’s alzheimer's disease alzheimer's
Stanley Black & Decker To Present At Deutsche Bank's Virtual Industrials Conference
Published: 2021-11-09 (Crawled : 23:00) - prnewswire.com
SWK | $90.18 -0.62% 180K
|
Consumer Durables
|
| O: 1.31%
H: 1.24%
C: -0.21%
trials trial conference
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection
Published: 2021-11-09 (Crawled : 22:00) - globenewswire.com
FNCH | $2.42 -13.22% 85K
|
Professional, Scientific, and T...
|
| O: 15.94%
H: 0.19%
C: -7.44%
phase 2 positive results topline trial injection infections
Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan
Published: 2021-11-09 (Crawled : 20:00) - biospace.com/
RAIN | $1.21 0.0% 3.7M
|
Manufacturing
|
| O: 0.36%
H: 0.0%
C: 0.0%
phase 2 trial cell carcinoma
Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting
Published: 2021-11-09 (Crawled : 19:00) - biospace.com/
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 1.47%
H: 2.91%
C: -2.42%
immunotherapy phase 1 renal positive therapy cancer phase 1b trial phase 2b cell carcinoma
Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-172154 and SL-279252
Published: 2021-11-09 (Crawled : 18:00) - globenewswire.com
STTK | $9.98 5.16% 95K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
ongoing clinical trials phase 1 trials trial
USD 679.48 Mn growth in Electronic Trial Master File Systems Market | Driven by Increasing Number of Clinical Trials | Technavio
Published: 2021-11-09 (Crawled : 17:00) - prnewswire.com
VEEV | $199.59 -0.75% 120K
|
Technology Services
|
| O: -0.07%
H: 0.0%
C: 0.0%
clinical trials trials growth trial
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
Published: 2021-11-09 (Crawled : 15:15) - biospace.com/
TAK | News | $13.23 -1.12% 300K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
EXEL | $23.63 1.46% 560K
|
Health Technology
|
| O: -0.69%
H: 0.83%
C: -1.02%
lung cancer cancer phase 3 trial enroll
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Published: 2021-11-09 (Crawled : 15:15) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.16%
H: 0.46%
C: -0.68%
treatment phase 2 sclerosis phase 2b trial enroll
Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Published: 2021-11-09 (Crawled : 15:00) - biospace.com/
ANVS | $12.5 5.22% 110K
|
Health Technology
|
| O: -1.11%
H: 0.94%
C: -13.85%
disease alzheimer clinical trials trials trial conference alzheimer’s alzheimer's disease alzheimer's
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME
Published: 2021-11-09 (Crawled : 14:00) - immatics.com
IMTX | $10.255 -1.58% 47K
|
Health Technology
|
| O: 0.08%
H: 2.07%
C: -13.92%
ongoing phase 1 trial ima203 solid tumors response phase 1b
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
Published: 2021-11-09 (Crawled : 14:00) - biospace.com/
ZYME | $8.59 0.35% 59K
|
Health Technology
|
| O: -5.47%
H: 0.0%
C: 0.0%
positive phase 3 trial her2+ her2- her2
SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp
Published: 2021-11-09 (Crawled : 14:00) - globenewswire.com
SCYX | $1.55 22K
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: 0.0%
phase 1 trial phase 2 phase 3
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
Published: 2021-11-09 (Crawled : 13:15) - biospace.com/
ALDX | $3.885 -0.64% 230K
|
Health Technology
|
| O: 1.11%
H: 3.41%
C: 1.76%
new drug dry eye disease eye application eye disease drug phase 3 trial submission enroll
Kennametal to Attend Baird 2021 Global Industrial Virtual Conference
Published: 2021-11-09 (Crawled : 13:00) - prnewswire.com
KMT | $24.135 -0.88% 86K
|
Producer Manufacturing
|
| O: 1.54%
H: 0.0%
C: 0.0%
trial conference
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Published: 2021-11-09 (Crawled : 12:15) - globenewswire.com
CMPS | $8.155 -1.15% 200K
|
Health Technology
|
| O: -17.57%
H: 3.31%
C: -11.45%
treatment positive therapy results topline depression trial comp360 psilocybin
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.2 60.0% 63M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.05 44.75% 13M
|
Technology Services
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.